#USA #San Diego #Clinical Trials #Oxford Finance #Inhibrx

Inhibrx-Biosciences Strengthens Its Financial Backbone

Inhibrx Biosciences, Inc. (Nasdaq: INBX), a leader in clinical-stage biopharmaceutical innovation, has recently disclosed an updated loan agreement that enhances its financial capabilities significantly. This new agreement with Oxford Finance LLC expands the company’s credit facility to an impressive total of $500 million, demonstrating strong institutional support for Inhibrx's ambitious clinical pipeline.

The New Loan Agreement Explained

Announced on July 16, 2026, the revised loan agreement, termed as the Second Amendment to the existing Loan and Security Agreement, aims to provide an additional tranche of up to $325 million. This tranche comprises an immediate injection of $100 million, designated as the Term C Loan, while an additional $225 million is available at the company's discretion, contingent on the lender's approval.

Prior to this amendment, Inhibrx had already utilized $175 million from the original credit facility. The latest funding milestone showcases the company’s commitment to maintaining steady momentum in its research and development efforts, particularly concerning its key therapeutic candidates, ozekibart (INBRX-109) and INBRX-106.

Strategic Significance of the Funding

Kelly Deck, Chief Financial Officer of Inhibrx, expressed enthusiasm about the expanded financial partnership with Oxford Finance, highlighting the long-term confidence the lenders have in the company’s clinical programs. This substantial financial support enables Inhibrx to sustain its forward momentum in developing innovative biologic therapies, thereby positioning the company to capitalize on promising upcoming data readouts.

The infusion of capital from the Term C Loan also includes an arrangement whereby the lenders were granted warrants to purchase 21,457 shares of common stock, underlining the financial synergy between Inhibrx and its partners. These warrants come with a strike price of $93.21 per share, reflecting the investment confidence in the company’s stock potential.

Continued Focus on Innovation

Inhibrx has carved a niche in developing therapeutic candidates that address complex disease biology through state-of-the-art protein engineering techniques. With a robust pipeline emphasizing unique targeted therapies, Inhibrx is poised to explore innovative solutions that meet unmet medical needs.

The company’s ongoing clinical trials, particularly those for ozekibart and INBRX-106, are seen as pivotal steps toward developing transformative treatment options. Both candidates utilize multivalent designs tailored to enhance therapeutic efficacy, which could lead to significant advancements in patient care.

Looking Ahead

As Inhibrx navigates the dynamic landscape of biopharmaceutical innovation, this latest financial maneuver not only showcases the trust lenders have in the company’s mission but also underscores the strategic approach towards advancing critical healthcare solutions. Observers and stakeholders will eagerly await upcoming milestones, as Inhibrx continues to push the boundaries of modern medicine.

For further details and updates on Inhibrx's pipeline and business activities, interested parties can visit the company’s website at www.inhibrx.com.

Conclusion

The partnership between Inhibrx and Oxford Finance is a testament to the growing confidence in biotech ventures, particularly those focused on clinical-stage innovation. With substantial financial backing, Inhibrx is strategically positioned to make impactful contributions to healthcare, ensuring that its ambitious clinical programs not only advance but potentially transform therapeutic landscapes.